المؤلفون: Britta Weigelt, Anne Pavlick, C. Kent Osborne, Marilyn M. Li, Kathleen A. Burke, Jorge S. Reis-Filho, Tao Wang, Fresia Pareja, Matthew P. Goetz, Rachel Schiff, Jenny C. Chang, Rita Nanda, Suzanne A. W. Fuqua, Carmine De Angelis, Ian E. Krop, Ingrid A. Mayer, Mothaffar F. Rimawi, Sabrina Herrera, Antonio C. Wolff, Andres Forero, Felipe C Geyer, Alejandro Contreras, Susan G. Hilsenbeck, Carolina Gutierrez

المساهمون: Rimawi, M. F., de Angelis, C., Contreras, A., Pareja, F., Geyer, F. C., Burke, K. A., Herrera, S., Wang, T., Mayer, I. A., Forero, A., Nanda, R., Goetz, M. P., Chang, J. C., Krop, I. E., Wolff, A. C., Pavlick, A. C., Fuqua, S. A. W., Gutierrez, C., Hilsenbeck, S. G., Li, M. M., Weigelt, B., Reis-Filho, J. S., Osborne, C. K., Schiff, R.

المصدر: Breast Cancer Research and Treatment. 167:731-740

مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, Receptor, ErbB-2, medicine.medical_treatment, Estrogen receptor, PIK3CA mutation, 0302 clinical medicine, Trastuzumab, Antineoplastic Combined Chemotherapy Protocols, skin and connective tissue diseases, Class I Phosphatidylinositol 3-Kinase, biology, Middle Aged, Neoadjuvant Therapy, Gene Expression Regulation, Neoplastic, PCR, 030220 oncology & carcinogenesis, Immunohistochemistry, Female, Breast Neoplasm, Human, medicine.drug, Adult, medicine.medical_specialty, Class I Phosphatidylinositol 3-Kinases, Breast Neoplasms, Antibodies, Monoclonal, Humanized, Lapatinib, Article, 03 medical and health sciences, Breast cancer, Internal medicine, medicine, Humans, PTEN, HER2-positive breast cancer, neoplasms, PI3K/AKT/mTOR pathway, Aged, Chemotherapy, Antineoplastic Combined Chemotherapy Protocol, business.industry, PTEN Phosphohydrolase, Quinazoline, medicine.disease, PTEN level, 030104 developmental biology, Mutation, Quinazolines, biology.protein, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46dbfe4f85e97a7e7e1ced400f550593Test
https://doi.org/10.1007/s10549-017-4533-9Test

المؤلفون: Rimawi M. F., de Angelis C., Contreras A., Pareja F., Geyer F. C., Burke K. A., Herrera S., Wang T., Mayer I. A., Forero A., Nanda R., Goetz M. P., Chang J. C., Krop I. E., Wolff A. C., Pavlick A. C., Fuqua S. A. W., Gutierrez C., Hilsenbeck S. G., Li M. M., Weigelt B., Reis-Filho J. S., Osborne C. K., Schiff R.

المساهمون: Rimawi, M. F., de Angelis, C., Contreras, A., Pareja, F., Geyer, F. C., Burke, K. A., Herrera, S., Wang, T., Mayer, I. A., Forero, A., Nanda, R., Goetz, M. P., Chang, J. C., Krop, I. E., Wolff, A. C., Pavlick, A. C., Fuqua, S. A. W., Gutierrez, C., Hilsenbeck, S. G., Li, M. M., Weigelt, B., Reis-Filho, J. S., Osborne, C. K., Schiff, R.

مصطلحات موضوعية: HER2-positive breast cancer, Lapatinib, PCR, PIK3CA mutation, PTEN level, Trastuzumab, Adult, Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocol, Breast Neoplasm, Class I Phosphatidylinositol 3-Kinase, Female, Gene Expression Regulation, Neoplastic, Human, Middle Aged, Mutation, Neoadjuvant Therapy, PTEN Phosphohydrolase, Quinazoline, Receptor, ErbB-2

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000424656700012; volume:167; issue:3; firstpage:731; lastpage:740; numberofpages:10; journal:BREAST CANCER RESEARCH AND TREATMENT; http://hdl.handle.net/11588/774045Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85033456556; www.wkap.nl/journalhome.htm/0167-6806

الإتاحة: https://doi.org/10.1007/s10549-017-4533-9Test
http://hdl.handle.net/11588/774045Test